Atlas Trials

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Clinical trial NCT06583486 · COMPLETED

Trial details

NCT number
NCT06583486
Sponsor
Chongqing Claruvis Pharmaceutical Co., Ltd.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Moderate to Severe Glabellar Lines
Start date
2024-03-19
Primary completion
2025-08-25
Enrollment
488

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.